Select Starting Material
Employing organoids for disease modeling and drug discovery begins with selecting the appropriate cell type(s). Pluripotent stem cells, established cell lines, primary cells or tissue samples are just a few possible starting cell types. For disease modeling, genetic modification (e.g., CRISPR) of stem cells or confirmation of primary samples should be conducted prior to organoid development. If using organoids for drug screening, it is important to incorporate a control population. Custom organoids are available to order through Molecular Devices’ 3D Ready Organoid Expansion Service. Other important considerations include selection of media, reagents and consumables.
Providing a unified data backbone, the Genedata Biopharma Platform streamlines and automates data capture, analysis and management to ensure original-tissue identity. This includes evaluation of cell morphology and genetic background using high-content imaging and NGS, and insights into cell biological function through analysis of flow cytometry and other functional assays.